ORAL PRESENTATIONS AND POSTERS

Oral presentations Mathieu Vinken.jpg

Oral Presentations

 

Oral presentations

  • 5th World Congress on Alternatives and Animal Use in the Life Sciences, 21-25/08/2005, Berlin-Germany: the effects of Trichostatin A on gap junctional intercellular communication in primary cultures of adult rat hepatocytes.

  • Journée Exceptionnelle Connexins, 25/05/2007, Paris-France: the effects of Trichostatin A on gap junctional intercellular communication in primary cultures of adult rat hepatocytes.

  • 1st annual carcinoGENOMICS consortium meeting, 06-08/11/2007, Valencia-Spain: Trichostatin A enhances gap junctional intercellular communication in primary cultures of adult rat hepatocytes.

  • Journal Club, 07/07/2009, Ghent-Belgium: connexin32 hemichannels facilitate the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death.

  • International Gap Junction Conference, 25-30/07/2009, Sedona-USA: connexin32 hemichannels facilitate the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death.

  • CarcinoGENOMICS workpackage 2 meeting, 17-18/08/2008, Gothenburg-Sweden: Trichostatin A-stabilized primary rat hepatocyte cultures: a concise overview.

  • 7th World Congress on Alternatives and Animal Use in the Life Sciences, 30/08-03/09/2009, Rome-Italy: restoration and maintenance of the in vivo-like hepatocellular homeostatic balance: key for the establishment of long-term liver-based in vitro models.

  • ESNATS summer school, 22-27/09/2009, Zermatt-Switzerland: restoration and maintenance of the in vivo-like hepatocellular homeostatic balance: key for the establishment of long-term liver-based in vitro models.

  • Research seminars: master of biomedical sciences in cell and gene therapy, 02/04/2010, Brussels-Belgium: connexin-related signaling in cell death.

  • ADMET: Translating Research into Clinical Outcome, 06-07/07/2011, London-United Kingdom: state-of-the-art overview of strategies for the establishment of liver-based in vitro systems for long-term pharmaco-toxicological testing.

  • 8th World Congress on Alternatives and Animal Use in the Life Sciences, 21-25/08/2011, Montréal-Canada: an introduction to epigenetics.

  • 8th World Congress on Alternatives and Animal Use in the Life Sciences, 21-25/08/2011, Montréal-Canada: the European Society of Toxicology In Vitro: a concise introduction.

  • Summer School of the Safety Evaluation Ultimately Replacing Animal Testing project cluster, 04-08/06/2012, Lisbon-Portugal: drug-induced liver injury: mechanisms, types and biomarkers.

  • Postgraduate course on gap junctions, connexins and their physiological and pathological roles, 24-28/09/2012, São Paulo-Brazil: study of connexins and the Department of Toxicology of the Vrije Universiteit Brussel (Free University Brussels)-Belgium.

  • 4th Journey of the Latin American Society of Toxicologic Pathology, 25/09/2012, São Paulo-Brazil: connexin and pannexin signalling in cell death and cell growth: relevance for liver physiology and liver pathology.

  • State-of-the-art lectures in Biomedicine, 03/10/2012, Antwerp-Belgium: connexin and pannexin signalling in cell death and cell growth: relevance for liver physiology and liver pathology.

  • 17th Conference of the European Society for Toxicology In Vitro, 16-19/10/2012, Lisbon-Portugal: the effect of epigenetic modification on drug transporters in primary hepatocyte cultures.

  • Winterschool of the HeMiBio project, 16/01/2013, Barcelona-Spain: drug-induced liver injury: mechanisms, types and biomarkers.

  • Human Toxicology Project Consortium meeting, 23-25/01/2013, Baltimore-USA: drug-induced liver injury: mechanisms and types.

  • ReLiver workshop, 20-22/02/2013, Heidelberg-Germany: drug-induced liver injury: mechanisms and types.

  • Summerschool of the DETECTIVE project, 10-14/06/2013, Slano-Croatia: introduction to drug-induced liver injury and adverse outcome pathways.

  • 49th Conference of the European Societies of Toxicology, 01-04/09/2013, Interlaken-Switzerland: the role of connexins and their channels in toxicity.

  • SEURAT-1 Stakeholders event, 05/09/2013, Brussels-Belgium: HeMiBio: engineering tissue.

  • XVIII Brazilian Congress of Toxicology, 07-10/10/2013, Porto Alegre-Brazil: in vitro models for the evaluation of hepatotoxicity.

  • Specialisation course in the generation and maintenance of laboratory animals, 19/10/2013, Sao Pãulo-Brazil: alternatives to animal testing in toxicology.

  • XXII Scientific week Benjamin Eurico Malucelli, 21/10/2013, São Paulo-Brazil, oral presentation: alternatives to animal testing in toxicology.

  • State-of-the-art lectures in Biomedicine, 18/12/2013, Antwerp-Belgium: in vitro models for the evaluation of hepatotoxicity.

  • Dutch Society of Toxicology meeting, 12/02/2014, Leiden-The Netherlands: the adverse outcome pathway concept: a novel and pragmatic tool in toxicology and risk assessment.

  • Research seminars: master of biomedical sciences in cell and gene therapy, 21/02/2014, Brussels-Belgium: the CONNECT project: connexins and pannexins as drug targets and biomarkers in acute and chronic liver disease.

  • Human Toxicology Project Consortium meeting, 25/03/2014, Phoenix-USA: development and use of hepatic AOPs in the SEURAT project cluster.

  • Connexins-Pannexins: WOG FWO meeting, 22-23/05/2014, Ghent-Belgium: protective effects of connexin43 signaling in experimentally induced acute liver failure in mouse.

  • 5th symposium of the Latin American Society of Toxicologic Pathology, 11-14/04/2014, São Paulo-Brazil: in vitro models for the evaluation of hepatotoxicity.

  • 5th symposium of the Latin American Society of Toxicologic Pathology, 11-14/04/2014, São Paulo-Brazil: hepatic adverse outcome pathway constructs: novel and pragmatic tools in toxicology and risk assessment.

  • NOTOX satellite meeting, 10/06/2014, Egmond aan zee-The Netherlands: development and use of hepatic AOPs in the SEURAT project cluster.

  • OECD meeting of the extended advisory group on molecular screening and toxicogenomics, 12-13/06/2014, Paris-France: development and application of a new AOP from BSEP inhibition to cholestasis.

  • 9th World Congress on Alternatives and Animal Use in the Life Sciences, 24-28/08/2014, Prague-Czech Republic: development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

  • NIH workshop, 03-05/09/2014, Bethesda-USA: testing of the predictive power and robustness of an AOP construct for bile salt export pump inhibition to cholestatic injury.

  • Research seminar Department of Clinical Analysis and Toxicology, University of São Paulo, 30/09/2014, São Paulo-Brazil: liver-based in vitro models: conventional and novel strategies.

  • Research seminar Masaryk University, 04/11/2014, Brno-Czech Republic: drug-induced liver injury: mechanisms, types and biomarkers.

  • Research seminar Masaryk University, 04/11/2014, Brno-Czech Republic: liver-based in vitro models: conventional and novel strategies.

  • Research seminar Masaryk University, 05/11/2014, Brno-Czech Republic: connexins and pannexins: targets and biomarkers of liver disease.

  • State-of-the-art lectures in Biomedicine, 05/11/2014, Antwerp-Belgium: in vitro models for the evaluation of hepatotoxicity.

  • Seminar at the University of Kansas Medical Center, 12/11/2014, Kansas City-USA: connexins and pannexins: targets and biomarkers of liver disease.

  • IVTIP meeting, 18/11/2014, Monte Carlo-Monaco: adverse outcome pathways: development and applications.

  • Research seminar Federal University of Minas Gerais, 10/12/2014, Belo Horizonte-Brazil: connexins and pannexins: targets and biomarkers of liver disease.

  • Applied in vitro toxicology course, 25-29/01/2015, Lisbon-Portugal:  general in vitro cytotoxicity and cell death assays.

  • Applied in vitro toxicology course, 25-29/01/2015, Lisbon-Portugal:  liver-based models for in vitro toxicology purposes.

  • Applied in vitro toxicology course, 25-29/01/2015, Lisbon-Portugal:  emerging topics in in vitro toxicology: adverse outcome pathways.

  • Research seminar University of Western Ontario, 06/03/2015, London-Canada: connexins and pannexins: targets and biomarkers of liver disease.

  • Research seminar Université de Poitiers, 17/03/2015, Poitiers-France: connexins and pannexins: targets and biomarkers of liver disease.

  • Society of Toxicology meeting, 22-26/03/2015, San Diego-USA: connexin signaling in liver toxicity and disease.

  • Society of Toxicology meeting, 22-26/03/2015, San Diego-USA: predictive power and robustness of an AOP construct for bile salt export pump inhibition to cholestatic injury.

  • Research seminar University of São Paulo, 16/04/2015, São Paulo-Brazil: connexins and pannexins: targets and biomarkers of liver disease.

  • 25th conference of the Society of Environmental Toxicology and Chemistry, 03-07/05/2015, Barcelona-Spain: development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

  • In Vitro Testing Industrial Platform Spring Meeting, 28-29/05/2015, Copenhagen-Denmark: mechanistic understanding of toxicity: an introduction to AOPs and their potential for in vitro testing application.

  • Long Range Science Strategy workshop Cosmetics Europe, 02-03/06/2015, Brussels-Belgium: validation and optimization of adverse outcome pathways: the new challenge.

  • Network Verification Challenge Jamboree, 15-18/06/2015, Barcelona-Spain: adverse outcome pathways as tools to assess drug-induced toxicity.

  • Second World Conference on Targeting Liver Disease, 25-26/06/2015, St-Julian’s-Malta: inhibition of pannexin1 channels alleviates acetaminophen-induced hepatotoxicity in mouse.

  • Gap Junction Conference: Therapeutic Applications, 24/09/2015, La Coruna-Spain: role of connexin and pannexin signaling in liver disease.

  • State-of-the-art lectures in Biomedicine, 14/10/2015, Antwerp-Belgium: in vitro models for the evaluation of hepatotoxicity.

  • HeMiBio International Symposium Biology meets technology for liver toxicity testing, 02-03/12/2015, Leuven-Belgium: adverse outcome pathways as tools to assess drug-induced toxicity.

  • Seminar SRM University, 27/01/2016, Chennai-India: liver-based in vitro models for toxicity testing.

  • Seminar SRM University, 27/01/2016, Chennai-India: adverse outcome pathways as tools to assess chemical toxicity.

  • University of Auckland, 08/03/2016, Auckland-New Zealand: role of connexins, pannexins and their channels in liver disease.

  • 2nd International Conference on Hepatology, 09-11/05/2016, Chicago-USA: connexins and pannexins as novel drug targets in the treatment of acute and chronic liver disease.

  • Applied in vitro toxicology course, 20-24/06/2016, Brasilia-Brazil: general in vitro cytotoxicity and cell death assays.

  • Applied in vitro toxicology course, 20-24/06/2016, Brasilia-Brazil: liver-based models for in vitro toxicology purposes.

  • Alternative Approaches for Acute Inhalation Toxicity to Address Global Regulatory and Non-regulatory Data Requirements Webinar Series, 12/07/2016, Brussels-Belgium: adverse outcome pathways as tools to assess chemical-induced toxicity.

  • 52th Conference of the European Societies of Toxicology, 04-07/09/2016, Seville-Spain: the adverse outcome pathway for cholestatic liver injury: from mechanisms to predictive human toxicology.

  • 27th Ion Channel Meeting, 11-14/09/2016, Sète-France: connexin and pannexin (hemi)channels as novel drug targets in liver disease.

  • Science Xpression Workshop, 26-28/09/2016, La Coruna-Spain: preparing and giving a scientific presentation: tips and tricks.

  • Science Xpression Workshop, 26-28/09/2016, La Coruna-Spain: writing a scientific abstract: tips and tricks.

  • Gap Junction Conference: Therapeutic Applications, 29/09/2016, La Coruna-Spain: connexins and pannexins as novel drug targets in the treatment of acute and chronic liver disease.

  • Research seminar Department of Clinical Analysis and Toxicology, University of São Paulo, 25/10/2016, São Paulo-Brazil: liver-based in vitro models: conventional and novel strategies.

  • Research seminar Department of Clinical Analysis and Toxicology, University of São Paulo, 31/10/2016, São Paulo-Brazil: liver metabolism: phase 0-III biotransformation.

  • Research seminar Department of Clinical Analysis and Toxicology, University of São Paulo, 31/10/2016, São Paulo-Brazil: liver toxicity: types and mechanisms.

  • State-of-the-art lectures in Biomedicine, 07/12/2016, Antwerp-Belgium: liver-based models for in vitro toxicology purposes.

  • Applied in vitro toxicology course, 08-13/01/2017, Belvaux-Luxembourg: general in vitro cytotoxicity and cell death assays.

  • Applied in vitro toxicology course, 08-13/01/2017, Belvaux-Luxembourg: liver-based models for in vitro toxicology purposes.

  • Applied in vitro toxicology course, 08-13/01/2017, Belvaux-Luxembourg: emerging topics in in vitro toxicology: adverse outcome pathways.

  • Adverse outcome pathways: emerging regulatory requirements and new in vitro models webinar series, 06/02/2017, Brussels-Belgium: adverse outcome pathways as tools to address chemically-induced liver toxicity.

  • Postgraduate Education in Toxicology: Toxicogenomics, 23/02/2017, Maastricht-The Netherlands: adverse outcome pathways.

  • Food for Thought ERC Edition, 17/03/2017, Brussels-Belgium: experience of an ERC Starting Grantee at VUB.

  • Royal Academy for Overseas Sciences, 28/03/2017, Brussels-Belgium: hoe start ik een academische onderzoeksgroep op in Brazilië: ervaring van een jonge Belgische onderzoeker.

  • British Toxicology Society Meeting, 03-05/04/2017, Liverpool-UK: adverse outcome pathways as tools to assess chemically induced liver toxicity.

  • Research seminar, 24/04/2017, Brussels-Belgium: current topics in toxicology: adverse outcome pathways

  • Symposium “AOPs: an alternative for risk assessment?” Société de Pharmaco-Toxicologie Cellulaire, 21/06/2017, Paris-France : development and validation of an AOP from bile salt pump inhibition to cholestasis.

  • CAAT-Academy training “Updates on the hepatotoxicity AOP landscape and on the ADMET field”, 22-23/06/2017, Rennes-France, development and validation of an AOP from bile salt pump inhibition to cholestasis.

  • Symposium “AOP course light”, UKEMS/BEMS/DEMS meeting, 25-28/06/2017, Leuven-Belgium: AOP background and principles.

  • 14th European ISSX meeting, 26-29/06/2017, Cologne-Germany: adverse outcome pathways as tools to assess drug-induced toxicity.

  • 10th World Congress Alternatives and Animal Use in the Life Sciences, 20-24/08/2017, Seattle-USA: omics-based in vitro verification of an adverse outcome pathway of cholestatic liver injury.

  • 10th World Congress Alternatives and Animal Use in the Life Sciences, 20-24/08/2017, Seattle-USA: the European Society of Toxicology In Vitro (ESTIV)’s activities in promoting in vitro and in silico computational toxicology.

  • Science Xpression Workshop, 25-29/09/2017, Santiago de Compostella-Spain: preparing and giving a scientific presentation: tips and tricks.

  • Science Xpression Workshop, 25-29/09/2017, Santiago de Compostella-Spain: writing a scientific abstract: tips and tricks.

  • Science Xpression Workshop, 25-29/09/2017, Santiago de Compostella-Spain: preparing and presenting a scientific poster: tips and tricks.

  • Gap Junction Conference: Therapeutic Applications, 28/09/2017, La Coruna-Spain: role of connexin hemichannels in acute and chronic liver disease.

  • State-of-the-art lectures in Biomedicine, 04/10/2017, Antwerp-Belgium: adverse outcome pathways: novel tools in (eco)toxicology and risk assessment.

  • Study day “Alternatives to animal experiments”, 05/10/2017, Brussels-Belgium: mechanistic toxicology as the basis for animal-free risk assessment.

  • Congress “Non-animal methods for toxicokinetics”, 16-20/10/2017, Leiden-The Netherlands: AOP framework: where do kinetics come in?

  • Seminar at the Environmental Protection Agency, 30/10/2017, Raleigh Durham-USA: development of a quantitative adverse outcome pathway network of cholestatic liver injury for animal-free chemical risk assessment.

  • 11th International Congress of Pharmaceutical Sciences, 15-18/11/2017, Ribeirão Preto-Brazil: liver-based in vitro models for pharmaco-toxicological testing.

  • 11th International Congress of Pharmaceutical Sciences, 15-18/11/2017, Ribeirão Preto-Brazil: the European Society of Toxicology In Vitro: overview and activities.

  • Seminar “Animal testing for human therapeutics?”, 12/01/2018, Utrecht-The Netherlands: liver-based in vitro models for pharmaco-toxicological testing.

  • Society of Toxicology meeting, 11-15/03/2018, San Antonio-USA: omics-based in vitro verification of an adverse outcome pathway of cholestatic liver injury.

  • Applied in vitro toxicology course, 08-13/04/2018, Utrecht-The Netherlands: general in vitro cytotoxicity and cell death assays.

  • Applied in vitro toxicology course, 08-13/04/2018, Utrecht-The Netherlands: liver-based models for in vitro toxicology purposes.

  • Applied in vitro toxicology course, 08-13/04/2018, Utrecht-The Netherlands: emerging topics in in vitro toxicology: adverse outcome pathways.

  • World Toxicologic Pathology Congress, 24-26/04/2018, São Paulo-Brazil: liver-based in vitro models for toxicity testing.

  • PI Centric Event, 17/05/2018, Brussels-Belgium: CONNECT: connexin and pannexins channels as drug targets and biomarkers in acute and chronic liver disease.

  • Galenus award ceremony, 29/05/2018, Brussels-Belgium: cellular communication as a novel pharmacological target for the treatment of liver disease.

  • 44th Annual Summer Meeting of the Toxicology Forum, 09-11/07/2018, Annapolis-USA: adverse outcome pathways as tools to predict liver toxicity in in vitro models.

  • 54th Congress of the European Societies of Toxicology, Brussels-Belgium, 02-05/09/2018: liver-based in vitro models for toxicity testing.

  • 54th Congress of the European Societies of Toxicology, Brussels-Belgium, 02-05/09/2018: pathway approaches in human toxicology: focus on liver toxicity AOPs.

  • “From nanotoxicology to nanomedicine”, Tallinn-Estonia, 07/09/2018: liver-based in vitro models for toxicity testing.

  • ASCCT-ESTIV Webinar Series, 20/09/2018, Brussels-Belgium: adverse outcome pathways: an update on progress and some near-term applications.

  • Science Xpression Workshop, 24-28/09/2018, Santiago de Compostella-Spain: preparing and giving a scientific presentation: tips and tricks.

  • Science Xpression Workshop, 24-28/09/2018, Santiago de Compostella-Spain: writing a scientific abstract: tips and tricks.

  • Science Xpression Workshop, 24-28/09/2018, Santiago de Compostella-Spain: preparing and presenting a scientific poster: tips and tricks.

  • Gap Junction Conference: Therapeutic Applications, 27/09/2018, La Coruna-Spain: role of connexin hemichannels in acute and chronic liver disease.

  • State-of-the-art lectures in Biomedicine, 07/11/2018, Antwerp-Belgium: liver-based in vitro models for toxicity testing.

  • “Fuckup night”, Brussels-Belgium, 29/11/2018: fuckup night.

  • “Application of non-animal approaches for decision-making in chemical safety assessment” workshop, 10-11/12/2018, London-UK : the use of AOPs for in vitro prediction of liver toxicity.

  • Postgraduate Education in Toxicology: Toxicogenomics, 21/02/2019, Maastricht-The Netherlands: adverse outcome pathways.

  • Society of Toxicology meeting, 10-14/03/2019, Baltimore-USA: mitochondrial toxicity: a frequent key event in adverse outcome pathways.

  • “Introduction to toxicology and ecotoxicology as the scientific basis for management of chemical risk” BelTox seminar, 19/03/2019, Brussels-Belgium: in vitro methods for hazard identification.

  • VUB Pop-up seminar, 05/04/2019, Brussels-Belgium: connexin hemichannels and pannexin channels as drug targets in liver toxicity and disease.

  • Applied in vitro toxicology course, 14-19/04/2019, Bucharest-Romania: general in vitro cytotoxicity and cell death assays.

  • Applied in vitro toxicology course, 14-19/04/2019, Bucharest-Romania: liver-based models for in vitro toxicology purposes.

  • Applied in vitro toxicology course, 14-19/04/2019, Bucharest-Romania: emerging topics in in vitro toxicology: adverse outcome pathways.

  • Research seminar, 02/05/2019, Split-Croatia: connexin hemichannels and pannexin channels as drug targets in liver toxicity and disease.

  • Molecular Toxicology Course, 26-29/06-2019, Izmir-Turkey: adverse outcome pathways: focus on mitotoxicity.

  • Molecular Toxicology Course, 26-29/06-2019, Izmir-Turkey: liver-based in vitro models: tools for molecular toxicology research.

  • International Gap Junction Conference, 27-31/07/2019, Victoria- Canada: connexin hemichannels and pannexin channels as drug targets in liver toxicity and disease.

  • 55th Congress of the European Societies of Toxicology, 08-11/09/2019, Helsinki-Finland: adverse outcome pathways and beyond.

  • 8th Annual Meeting of the ASCCT "Computational toxicology: peeking into the clouds while keeping our feet on solid ground", 24-26/09/2019, Gaithersburg-USA: 2019-2020 conferences: ESTIV2020, WC11 and P2P.

  • epaa workshop "New ideas for systemic toxicity", 01-02/10/2019, Brussels-Belgium: development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study.

  • EBTC-EFSA workshop "Advancing the application of evidence-based methods to construct mechanistic frameworks for the development and use of non-animal toxicity tests", 02-03/10/2019, Parma-Italy: the use of adverse outcome pathways for in vitro prediction of liver toxicity.

  • Science Xpression Workshop, 07-11/10/2019, La Coruna-Spain: preparing and giving a scientific presentation: tips and tricks.

  • Science Xpression Workshop, 07-11/10/2019, La Coruna-Spain: writing a scientific abstract: tips and tricks.

  • Gap Junction Conference: connexin and pannexin channels in inflammation, tissue regeneration and cancer, 08/10/2019, La Coruna-Spain: connexin hemichannels and pannexin channels as drug targets in liver toxicity and disease.

  • 10th International Congress of the Turkish Society of Toxicology, 16/10-19/10/2019, Antalya-Turkey: adverse outcome pathways associated with mitochondria.

  • International Industrial and Environmental Toxicology Congress, 26/10-29/10/2019, Antalya-Turkey: liver-based in vitro models for toxicity testing.

  • Pioneer-2-Policymaker Conference "Accelerating the transition towards animal-free innovations", 27-29/11/2019, Utrecht-The Netherlands: the use of adverse outcome pathways for in vitro prediction of liver toxicity.

  • State-of-the-art lectures in Biomedicine, 18/12/2019, Antwerp-Belgium: liver-based in vitro models for toxicity testing.

  • Seminar University of Wageningen, 16/01/2020, Wageningen-The Netherlands: the use of adverse outcome pathways for in vitro prediction of liver toxicity.

  • Liver Systems Medicine Retreat, 29/01-31/01/2020, Hofgeismar-Germany: liver-based in vitro models for toxicity testing.

  • Liver Systems Medicine Retreat, 29/01-31/01/2020, Hofgeismar-Germany: connexin hemichannels and pannexin channels as drug targets in liver toxicity and disease.

  • BelTox seminar “Introduction to toxicology and ecotoxicology as the scientific basis for management of chemical risk”, 18/02/2020, Brussels-Belgium: in vitro methods for hazard identification.

  • OECD webinar, 09/07/2020: 3Rs projects funded by the European Commission: AOP case study.

  • OpenTox2020 Virtual Conference, 21/09-25/09-2020, oral presentation (invited speaker): development, quantification and application of an adverse outcome pathway network of cholestatic liver injury.

  • Applied in vitro toxicology course, 25-30/10/2020, Brussels-Belgium: general in vitro cytotoxicity and cell death assays.

  • Applied in vitro toxicology course, 25-30/10/2020, Brussels-Belgium: liver-based models for in vitro toxicology purposes.

  • Applied in vitro toxicology course, 25-30/10/2020, Brussels-Belgium: emerging topics in in vitro toxicology: adverse outcome pathways.

 

Poster presentations

  • Cell signaling, transcription and translation as therapeutic targets, 30/01-02/02/2002, Luxemburg-Luxemburg: phase I biotransformation of Trichostatin A, a histone deacetylase inhibitor, in suspensions of freshly isolated rat hepatocytes, and in human and rat liver microsomes.

  • Annual BelTox meeting, 29/11/2002, Brussels-Belgium: phase I biotransformation of Trichostatin A, a histone deacetylase inhibitor, in suspensions of freshly isolated rat hepatocytes, and in human and rat liver microsomes.

  • Hepatocyte Users Group meeting, 12-13/11/2004, Valencia-Spain: the effect of Trichostatin A on gap junctional intercellular communication in primary cultures of rat hepatocytes.

  • Discovery on Target: histone deacetylase inhibitors, 16-17/10/2007, Boston-USA: Trichostatin A enhances gap junctional intercellular communication in primary cultures of adult rat hepatocytes.

  • 1st annual carcinoGENOMICS consortium meeting, 06-08/11/2007, Valencia-Spain: Trichostatin A enhances gap junctional intercellular communication in primary cultures of adult rat hepatocytes.

  • 3rd annual meeting of the European Partnership for Alternative Approaches to Animal Testing, 03/11/2008, Brussels-Belgium: establishment of an in vitro model of liver cell death.

  • ESNATS summer school, 22-27/09/2009, Zermatt-Switzerland: connexin32 hemichannels facilitate the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death.

  • 4th annual meeting of the European Partnership for Alternative Approaches to Animal Testing, 06/11/2009, Brussels-Belgium: data sharing on compound selection: a way to improve the outcome of research projects in the field of 3R-alternatives to animal testing.

  • Cold Spring Harbor Asia Conference on Epigenetics, Chromatin and Transcription, 17-21/05/2010, Suzhou-China: the novel histone deacetylase inhibitor 4-Me2N-BAVAH enhances functional differentiation in cultures of primary hepatocytes.

  • 16th Conference of the European Society for Toxicology In Vitro, 02-04/09/2010, Linz-Austria: connexin32 hemichannels facilitate the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death.

  • 50th Society of Toxicology Meeting, 06-10/03/2011, Washington DC-USA: connexin32 hemichannels facilitate the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death.

  • International Gap Junction Conference, 06-11/08/2011, Ghent-Belgium: connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes.

  • 8th World Congress on Alternatives and Animal Use in the Life Sciences, 21-25/08/2011, Montréal-Canada: connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes.

  • Annual meeting of the Safety Evaluation Ultimately Replacing Animal Testing project cluster, 08-09/02/2012, Lisbon-Portugal: connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes.

  • Summer School of the Safety Evaluation Ultimately Replacing Animal Testing project cluster, 04-08/06/2012, Lisbon-Portugal: connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes.

  • International Gap Junction Conference, 13-18/07/2013, Charleston-USA: connexin43 signalling triggers dedifferentiation in cultures of primary hepatocytes by facilitating spontaneous apoptosis.

  • Annual meeting of the Safety Evaluation Ultimately Replacing Animal Testing project cluster, 05-06/02/2014, Barcelona-Spain: development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

  • Society of Toxicology meeting, 23-27/03/2014, Phoenix-USA: development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

  • NC3R workshop, 08-09/05/2014, London-UK: development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

  • SEURAT summer school, 08-10/06/2014, Egmond aan Zee-The Netherlands: development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

  • 18th Conference of the European Society for Toxicology In Vitro, 10-13/06/2014, Egmond aan Zee-The Netherlands: development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

  • 25th Asian Pacific Association for the Study of the Liver, 20-24/02/2016, Tokyo-Japan: inhibition of pannexin1 channels alleviates acetaminophen-induced hepatotoxicity in mouse.

  • NC3R workshop, 28/04/2016, London-UK: in vitro verification of an adverse outcome pathway of cholestasis.

  • 67th American Association for the Study of Liver Diseases Meeting, 11-15/11/2016, Boston-USA: in vitro verification of an adverse outcome pathway of cholestasis.

  • 67th American Association for the Study of Liver Diseases Meeting, 11-15/11/2016, Boston-USA: pannexin1 channel inhibition attenuates neutrophil recruitment upon acetaminophen-induced hepatotoxicity.

  • 53rd Congress of the European Societies of Toxicology, 10-13/09/2017, Bratislava-Slovakia: omics-based in vitro verification of an adverse outcome pathway of cholestatic liver injury.

  • CEFIC LRI workshop, 14-15/11/2018, Brussels-Belgium: development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study.

  • 15th IUTOX International Congress of Toxicology, 15-18/07/2019, Honolulu-USA: connexin hemichannels and pannexin channels as drug targets in liver toxicity and disease.

  • 55th Congress of the European Societies of Toxicology, 08-11/09/2019, Helsinki-Finland: connexin hemichannels and pannexin channels as drug targets in liver toxicity and disease.

  • The Liver Meeting, 08-12/11/2019, Boston-USA: connexin hemichannels and pannexin channels as drug targets in liver toxicity and disease.

  • 14th IEEE International Conference on Semantic Computing, 03-05/02/2020, San Diego-USA: facilitating data curation: a solution developed in the toxicology domain.

  • 9th ASCCT meeting, 20-23/10/2020, virtual meting: a robust mechanistically-based in silico profiler for cholestatic liver injury.